Short term safety of coronavirus disease 2019 vaccines in patients with solid tumors receiving systemic therapy

作     者：Ronald E Cox Marie Parish Carolyn Oxencis Edward Mckenna Bicky Thapa Sakti Chakrabarti 

作者机构：StudentMedical College of WisconsinWauwatosaWI 53222United States PharmacyFroedtert&the Medical College of WisconsinWauwatosaWI 53222United States Department of Hematology and OncologyMedical College of WisconsinWauwatosaWI 53222United States 

出 版 物：《World Journal of Clinical Oncology》 (世界临床肿瘤学杂志（英文版）)

年 卷 期：2022年第13卷第7期

页      面：599-608页

学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

主　　题：COVID-19 Adverse events Solid tumor Chemotherapy Immunotherapy Targeted therapy 

摘      要：BACKGROUND There are currently three coronavirus disease 2019(COVID-19)vaccines approved by the United States Food and Drug Administration to prevent coronavirus ***,robust data are unavailable on the adverse events of the vaccines in patients with solid tumor malignancies undergoing systemic *** To evaluate the safety of COVID-19 vaccines in patients with solid tumors undergoing systemic *** The study included patients with solid tumors treated in an academic tertiary care center who received COVID-19 vaccination between January 1,2021 and August 15,2021,while undergoing systemic *** medical records were accessed to collect information on patient characteristics,systemic therapies,type of vaccine received,and adverse effects associated with the vaccine *** events(AEs)were graded according to Common Terminology Criteria for Adverse Events,version *** The analysis included 210 patients;the median age was 70 years,and 51%of patients were *** most common chemotherapy,immunotherapy,and targeted therapy administered were taxane-based regimens 14.2%(30/210),antiprogrammed death 1(PD-1)agents 22.8%(48/210),and antiangiogenic agents 7.1%(15/210),*** most common cancers were gastrointestinal 43.8%(92/210),thoracic 30.4%(64/210),and genitourinary 17.6%(37/210).Patients received the following vaccines:2 doses of BNT162b2 by Pfizer 52%(110/210),2 doses of mRNA-1273 by Moderna 42%(89/210),and 1 dose of JNJ-78436735 by Johnson&Johnson 5%(11/210).At least 1 AE attributable to the vaccine was observed in 37 patients 17.6%(37/210).The total number of AEs attributable to vaccines was 62:Fifty-three grade 1 and nine grade *** adverse events occurred after the second dose 59.7%(37/62).The most frequent grade 1 AEs included fatigue 17%(9/53),fever 15%(8/53),injection site reaction 13.2%(7/53),and chills 9.4%(5/53).The most frequent grade 2 AEs were fatigue 33.3%(3/9)and generalized wea